Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/80831
DC Field | Value | Language |
---|---|---|
dc.contributor | School of Nursing | en_US |
dc.creator | Molassiotis, A | en_US |
dc.creator | Cheng, HL | en_US |
dc.creator | Leung, KT | en_US |
dc.creator | Li, YC | en_US |
dc.creator | Wong, KH | en_US |
dc.creator | Au, JSK | en_US |
dc.creator | Sundar, R | en_US |
dc.creator | Chan, A | en_US |
dc.creator | Ng, TRD | en_US |
dc.creator | Suen, LKP | en_US |
dc.creator | Chan, CW | en_US |
dc.creator | Yorke, J | en_US |
dc.creator | Lopez, V | en_US |
dc.date.accessioned | 2019-06-12T08:16:55Z | - |
dc.date.available | 2019-06-12T08:16:55Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/80831 | - |
dc.language.iso | en | en_US |
dc.publisher | John Wiley & Sons | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | en_US |
dc.rights | © 2019 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. | en_US |
dc.rights | The following publication Molassiotis, A, Cheng, HL, Leung, KT, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019; 9:e01312 is available at https://dx.doi.org/10.1002/brb3.1312 | en_US |
dc.subject | Cancer | en_US |
dc.subject | Chemotherapy‐induced peripheral neuropathy | en_US |
dc.subject | Platinum chemotherapy | en_US |
dc.subject | Risk factors | en_US |
dc.subject | Taxanes | en_US |
dc.title | Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.volume | 9 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.doi | 10.1002/brb3.1312 | en_US |
dcterms.abstract | Background: Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant and difficult to manage side effect of neurotoxic chemotherapies. Several risk factors for CIPN have been identified to date, but inconsistencies and methodological limitations exist in past research. Also, a limited number of potential risk factors has been investigated in the past. | en_US |
dcterms.abstract | Aim: The objective of this study was to assess the relative contribution of a wider range of risk factors in the development of CIPN. | en_US |
dcterms.abstract | Methods: This analysis used the 6‐month data after starting chemotherapy from a larger prospective observational study on CIPN risk, prevalence, and quality of life. Patients were assessed at recruitment for possible CIPN risk factors, including prior history of neuropathies, current/past infectious diseases; neurotoxic medication history; personal and treatment characteristics; smoking history, alcohol use, and vegetable/fruit intake. Neuropathy was assessed at 6‐months after starting chemotherapy with the neuropathy (motor/sensory) items of the NCI‐CTCAE scale and the WHO criterion for neuropathy. Data on symptom burden were also collected. | en_US |
dcterms.abstract | Results: Data were available from 255 patients from three cancer centers in Hong Kong, Singapore, and UK. The use of different scales did not always identify the same predictor variables. Key risk factors in multivariate regression models included older age (highest OR = 1.08, p < 0.01 with the WHO scale), chemotherapy (platinum‐based chemotherapy had OR = 0.20–0.27 in developing CIPN compared to taxane‐based chemotherapy), history of neuropathy (for motor CIPN only, OR = 8.36, p < 0.01), symptom burden (OR = 1.06, p < 0.05), number of chemotherapy cycles received (OR = 1.19–1.24, p < 0.01), and alcohol intake (OR = 0.32, p < 0.05). In univariate analysis, the use of statins was implicated with CIPN (p = 0.03–0.04 with different assessments) and diabetes showed a trend (p = 0.09) in the development of CIPN. | en_US |
dcterms.abstract | Conclusion: This study confirmed the CIPN risk related to certain variables and identified new ones. This knowledge can assist with treatment decisions and patient education. | en_US |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Brain and behavior, June 2019, v. 9, no. 6, e01312 | en_US |
dcterms.isPartOf | Brain and behavior | en_US |
dcterms.issued | 2019-06 | - |
dc.identifier.ros | 2018000075 | - |
dc.identifier.eissn | 2162-3279 | en_US |
dc.identifier.artn | e01312 | en_US |
dc.description.validate | 201906 bcrc | en_US |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | a0307-n11 | - |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Molassiotis_Risk_Chemotherapy‐induced_Neuropathy.pdf | 453.14 kB | Adobe PDF | View/Open |
Page views
135
Last Week
0
0
Last month
Citations as of Apr 14, 2024
Downloads
14
Citations as of Apr 14, 2024
SCOPUSTM
Citations
71
Citations as of Mar 29, 2024
WEB OF SCIENCETM
Citations
63
Citations as of Apr 18, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.